口服cedazuridine/地西他滨治疗MDS和CMML的2期药代/药效随机交叉研究
这项2期随机交叉研究比较了口服cedazuridine 100 mg/地西他滨35 mg与标准静脉地西他滨20 mg/m2在MDS或CMML患者前2个周期的全身暴露、去甲基化活性和安全性。共80例患者随机治疗,口服/静脉5天AUClast几何均值比在剂量确认阶段为93.5%,固定剂量复方阶段为97.6%,LINE-1去甲基化差异≤1%,临床反应率60%(完全缓解21%)。
要点
- 口服cedazuridine/地西他滨与静脉地西他滨的5天AUClast几何均值比接近100%。
- 口服与静脉地西他滨的LINE-1 DNA去甲基化差异≤1%。
- 临床反应率60%,其中完全缓解21%。
核心结论
- 口服cedazuridine/地西他滨(100/35 mg)在前2个周期产生的全身地西他滨暴露、DNA去甲基化和安全性与静脉地西他滨20 mg/m2相似,疗效也相似。
研究设计与样本
- 2期随机交叉研究,比较口服cedazuridine/地西他滨与静脉地西他滨在前2个周期的药代动力学、药效动力学和安全性。
- 纳入国际预后评分系统中危-1/2或高危的骨髓增生异常综合征(MDS)或慢性粒单核细胞白血病(CMML)成人患者,1:1随机分配至第1周期口服或静脉治疗,第2周期交叉,后续周期均接受口服治疗。
- 共80例患者随机并接受治疗。
- cedazuridine和地西他滨最初以分开胶囊给药(剂量确认阶段),之后以固定剂量复方片剂给药。
主要发现
- 口服/静脉5天AUClast几何均值比(80%置信区间)在剂量确认阶段为93.5%(82.1-106.5),在固定剂量复方阶段为97.6%(80.5-118.3)。
- 口服与静脉地西他滨的平均LINE-1去甲基化百分比差异≤1%。
- 48例患者(60%)观察到临床反应,其中17例(21%)为完全缓解。
- 无论因果关系,最常见的≥3级不良事件为中性粒细胞减少(46%)、血小板减少(38%)和发热性中性粒细胞减少(29%)。
关键数值与推荐
- 主要终点包括口服/静脉5天AUClast的几何最小二乘均值、LINE-1 DNA去甲基化百分比和临床反应。
- 口服/静脉5天AUClast几何均值比在剂量确认阶段为93.5%(80% CI 82.1-106.5),固定剂量复方阶段为97.6%(80% CI 80.5-118.3)。
- 口服与静脉地西他滨的平均LINE-1去甲基化差异≤1%。
- 临床反应率60%,完全缓解率21%。
临床怎么用
- 口服cedazuridine/地西他滨(100/35 mg)可作为静脉地西他滨20 mg/m2的替代方案,在前2个周期提供相似的全身暴露、去甲基化活性和安全性。
- 治疗期间需监测≥3级不良事件,尤其是中性粒细胞减少、血小板减少和发热性中性粒细胞减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This phase 2 study was designed to compare systemic decitabine exposure, demethylation activity, and safety in the first 2 cycles with cedazuridine 100 mg/decitabine 35 mg vs standard decitabine 20 mg/m2 IV. Adults with International Prognostic Scoring System intermediate-1/2- or high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) were randomized 1:1 to receive oral cedazuridine/decitabine or IV decitabine in cycle 1, followed by crossover to the other treatment in cycle 2. All patients received oral cedazuridine/decitabine in subsequent cycles. Cedazuridine and decitabine were given initially as separate capsules in a dose-confirmation stage and then as a single fixed-dose combination (FDC) tablet. Primary end points: mean decitabine systemic exposure (geometric least-squares mean [LSM]) of oral/IV 5-day area under curve from time 0 to last measurable concentration (AUClast), percentage long interspersed nuclear element 1 (LINE-1) DNA demethylation for oral cedazuridine/decitabine vs IV decitabine, and clinical response. Eighty patients were randomized and treated. Oral/IV ratios of geometric LSM 5-day AUClast (80% confidence interval) were 93.5% (82.1-106.5) and 97.6% (80.5-118.3) for the dose-confirmation and FDC stages, respectively. Differences in mean %LINE-1 demethylation between oral and IV were ≤1%. Clinical responses were observed in 48 patients (60%), including 17 (21%) with complete response. The most common grade ≥3 adverse events regardless of causality were neutropenia (46%), thrombocytopenia (38%), and febrile neutropenia (29%). Oral cedazuridine/decitabine (100/35 mg) produced similar systemic decitabine exposure, DNA demethylation, and safety vs decitabine 20 mg/m2 IV in the first 2 cycles, with similar efficacy. This study is registered at www.clinicaltrials.gov as #NCT02103478.
引用
- Garcia-Manero G, Griffiths EA, Steensma DP, et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020. PMID: 32285126. doi:10.1182/blood.2019004143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。